APOB and steatosis: We believe that the improvement in steatosis is mainly caused by the direct effect of MDM2 inactivation on ApoB expression and TG‐VLDL secretion, whereas the alleviation of inflammation and fibrosis may be secondary to the relief from lipotoxicity in hepatocytes.